MedTrace Logo

A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure

NCT07219849 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2025-10-22

No results posted yet for this study

Summary

This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.

Conditions

  • Seasonal Allergic Rhinitis (SAR)

Interventions

DRUG

ALDP001 Nasal Spray

Experimental Arm

DRUG

Placebo Nasal spray

Controlled arm

Sponsors & Collaborators

  • Alixer Nexgen Therapeutics Limited

    lead INDUSTRY

Principal Investigators

  • Patricia Couroux, MD · Cliantha Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-17
Primary Completion
2026-04-30
Completion
2026-04-30
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07219849 on ClinicalTrials.gov